Safety and effectiveness of left atrial appendage occlusion in patients with atrial fibrillation and high bleeding risk: a cardinality-matched comparison with direct oral anticoagulation on long-term stroke and bleeding rates
Swiss Medical Weekly · 2025
DOI: 10.57187/s.4288 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Swiss Medical Weekly, 2025. Verfasst von Thomas Gilhofer und 30 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, University Heart Centre, University Hospital Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Atrial Fibrillation, Atrial Appendage, Stroke, Hemorrhage. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Schlaganfall
Abstract (Originalsprache)
STUDY AIMS: Left atrial appendage occlusion (LAAO) is an accepted alternative stroke prevention strategy for patients with atrial fibrillation (AF) and contraindications to oral anticoagulation despite the lack of randomised data in this population. This study aims to compare the outcomes of LAAO and direct oral anticoagulation (DOAC) therapy in patients with high bleeding risk. METHODS: This cardinality-matched analysis comprised data from the Beat-AF and Swiss-AF cohorts (n = 3960; enrolment from 2010 to 2014 and from 2014 to 2017, respectively), along with the Zurich LAAO Registry (n = 535; patients included between 2010 and 2023). The primary endpoint was a composite of stroke, cardiovascular death or major bleeding. The individual components constituted the secondary endpoints. Time-dependent cumulative incidence curves were constructed and a competing risk analysis was included. RESULTS: After matching, 478 patients with a DOAC score ≥8 and 159 patients with previous major bleeding were compared in a 1:1 and 1:2 ratio, respectively, regarding their stroke prevention strategy (DOAC versus LAAO). After a median follow-up time of 4.9 years (interquartile range [IQR]: 2.2–6.1) in all patients with a DOAC score ≥8 and 4.4 years (IQR: 2.0–6.0) in all patients with previous major bleeding, there were no significant differences in the primary endpoint (hazard ratio [HR]: 0.88, 95% confidence interval [CI]: 0.67–1.14, p = 0.33 and HR: 0.79, 95% CI: 0.50–1.27, p = 0.33) and in the rates of stroke (HR: 0.74, 95% CI: 0.39–1.42, p = 0.36 and HR: 1.09, 95% CI: 0.33–3.62, p = 0.89) and cardiovascular death (HR: 0.97, 95% CI: 0.68–1.38, p = 0.85 and HR: 0.91, 95% CI: 0.50–1.64, p = 0.74). The rate of major bleedings was significantly lower in the LAAO group of both cohorts (HR: 0.55, 95% CI: 0.32–0.94, p = 0.029 and HR: 0.32, 95% CI: 0.13–0.79, p = 0.013). CONCLUSION: In this high bleeding risk population, LAAO was associated with similar effectiveness in preventing atrial fibrillation-related stroke and cardiovascular death and significantly lower rates of major bleeding compared to DOAC therapy. This strengthens the value of LAAO as an alternative stroke prevention strategy for patients at high risk of bleeding.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cardiology, University Heart Centre, University Hospital Zurich, Zurich, Switzerland.
- Department of Cardiology, Cantonal Hospital Winterthur, Winterthur, Switzerland.
- Deutsches Herzzentrum der Charité, Campus Virchow-Klinikum, Berlin, Germany.
- Department of Cardiology, Hospital St. Gallen, St. Gallen, Switzerland.
- Department of Internal Medicine, Hospital Zollikerberg, Zollikerberg, Switzerland.
- Internal Medicine B, University Medicine Greifswald, Greifswald, Germany.
ORCID-Profile: Thomas Gilhofer, Victoria Bokemeyer, Mario Gehler, Mi Chen, Alessandro Candreva, Davide Di Vece, Barbara E Stähli, Alexander Gotschy, Philipp Jakob, Frank Ruschitzka, Philipp Krisai, Leo H Bonati, Moa Lina Haller, Juerg H Beer, Peter Ammann, Giorgio Moschovitis, Elia Rigamonti, David Conen, Ronald Karl Binder, Tobias Reichlin, Michael Kühne
Zitieren
APA
Gilhofer, T., Schweiger, V., Bokemeyer, V., Gehler, M., Michel, J. M., Chen, M., Candreva, A., Ryberg, L., Di Vece, D., Templin, C., Stähli, B. E., Stehli, J., Gotschy, A., Jakob, P., Ruschitzka, F., Aeschbacher, S., Krisai, P., Bonati, L. H., Haller, M. L., …, & Kasel, A. M. (2025). Safety and effectiveness of left atrial appendage occlusion in patients with atrial fibrillation and high bleeding risk: a cardinality-matched comparison with direct oral anticoagulation on long-term stroke and bleeding rates. Swiss Medical Weekly. https://doi.org/10.57187/s.4288
Vancouver
Gilhofer T, Schweiger V, Bokemeyer V, Gehler M, Michel JM, Chen M, et al. Safety and effectiveness of left atrial appendage occlusion in patients with atrial fibrillation and high bleeding risk: a cardinality-matched comparison with direct oral anticoagulation on long-term stroke and bleeding rates. Swiss Medical Weekly. 2025. doi:10.57187/s.4288
BibTeX
@article{Gilhofer2025,
author = {Gilhofer, Thomas and Schweiger, Victor and Bokemeyer, Victoria and Gehler, Mario and Michel, Jonathan M and Chen, Mi and Candreva, Alessandro and Ryberg, Linn and Di Vece, Davide and Templin, Christian and Stähli, Barbara E and Stehli, Julia and Gotschy, Alexander and Jakob, Philipp and Ruschitzka, Frank and Aeschbacher, Stefanie and Krisai, Philipp and Bonati, Leo H and Haller, Moa Lina and Rodondi, Nicolas and Beer, Juerg H and Ammann, Peter and Moschovitis, Giorgio and Rigamonti, Elia and Osswald, Stefan and Conen, David and Nietlispach, Fabian and Binder, Ronald Karl and Reichlin, Tobias and Kühne, Michael and Kasel, Albert Markus},
title = {Safety and effectiveness of left atrial appendage occlusion in patients with atrial fibrillation and high bleeding risk: a cardinality-matched comparison with direct oral anticoagulation on long-term stroke and bleeding rates},
journal = {Swiss Medical Weekly},
year = {2025},
doi = {10.57187/s.4288}
}
EUVIMED